Patients must have confirmed stage IA-IIB mycosis fungoides.
Patients must be 18-90 years of age.
Patients must have failed at least one standard therapy for MF.
Patients must have active, but stable disease for \>6 months.
Patients must have 4 or more discrete MF lesions with at least 2 of them with minimum combined surface area of \>50cm2.
POCBP must have a negative pregnancy test prior to registration on study.
Patients must have the ability to understand and the willingness to sign a written informed consent document.
You may not be if
Patients who are on current systemic or topical CTCL therapy, unless stable on the treatment for \>6 months.
Patients who have received antibiotic therapy within 4 weeks of study enrollment.
Patients who are pregnant or nursing. Pregnant people are excluded from this study because IMQ is an agent with potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the gestational parent with IMQ, breastfeeding should be discontinued if the parent is treated with IMQ.
Patients with psychiatric illness/social situations that would limit compliance with study requirements.
